Shots:

• The P-III KEYNOTE-564 evaluating Keytruda monothx (200 mg- IV- on day1 of each 3wks. cycle for up to 17 cycles) vs PBO in 950 patients with RCC- following nephrectomy & resection of metastatic lesions
• Results: @ median follow-up of 24.1 mos.- 32% reduction in the risk of disease recurrence or death- a favorable trend in OS was observed with 46% reduction in risk of death
• Keytruda is currently approved in the US- EU & Japan in combination with axitinib as a 1L treatment for advanced RCC. The company continues to evaluate the therapy in combination or as monothx across multiple settings & stages of RCC through its broad clinical program include 20 clinical studies & 4-000+ patients

Ref: Businesswire | Image: Merck